Top

Published in:

28-06-2023 | Cholangiocarcinoma

An Overview of the Therapeutic Development of Cholangiocarcinoma with Special Emphasis on Targeted and Biologic Therapies

Authors: Paulina S. Marell, Jana Wieland, Hani M. Babiker, Lionel Kankeu Fonkoua, Mitesh J. Borad, Aminah Jatoi, Nguyen H. Tran

Published in: Current Hepatology Reports | Issue 3/2023

Abstract

Purpose of Review

Cholangiocarcinoma remains difficult to treat with a poor prognosis. Nevertheless, the treatment landscape is rapidly evolving to include chemotherapy, immunotherapy, and targeted therapies. This paper will summarize recent developments in targeted therapies.

Recent Findings

Gemcitabine/cisplatin plus durvalumab or pembrolizumab is the standard first-line treatment for patients with advanced cholangiocarcinoma. Multiple alterations have been identified with corresponding approved targeted agents, including fibroblast growth factor receptor inhibitors pemigatinib, infigratinib, and futibatinib; the isocitrate dehydrogenase 1 inhibitor ivosidenib; and the inhibitors of encoded kinases of NTRK1-3 entrectinib and larotrectinib. In tumors with microsatellite instability or deficient mismatch repair, pembrolizumab is approved. Dabrafenib and trametinib also received tumor agnostic approval for BRAF V600E mutations. Additional emerging targets include HER2 and DNA repair pathways.

Summary

Multiple targeted therapies are currently approved in the treatment of advanced cholangiocarcinoma, and many more molecular alterations or pathways have been identified as promising therapeutic targets.

1.••

Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(5):541–65. Updated guidelines for the treatment of cholangiocarcinoma.PubMedCrossRef

Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin North Am. 2019;99(2):315–35.PubMedCrossRef

Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A, Valle JW, Ducreux M. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–40. https://doi.org/10.1016/j.annonc.2022.10.506.

Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391–8.PubMedCrossRef

5.••

Oh D-Y, He AR, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. 2022;1(8):EVIDoa200015. Most recent phase III clinical trial to demonstrate clinical benefit of adding immunotherapy to first line treatment in cholangiocarcinoma.CrossRef

6.••

Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A. KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853–65. https://doi.org/10.1016/S0140-6736(23)00727-4. Largest phase III clinical trial to date to demonstrate yet again the addition of immunotherapy to first-line treatment in improving overall survival.

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–10.PubMedCrossRef

Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68(5):959–69.PubMedCrossRef

Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116–35.PubMedPubMedCentralCrossRef

10.

Kendre G, Marhenke S, Lorz G, Becker D, Reineke-Plaaß T, Poth T, et al. The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion-driven cholangiocarcinoma. Hepatology. 2021;74(3):1357–70.PubMedCrossRef

11.

Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year Trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594–9.PubMedPubMedCentralCrossRef

12.

Mukkamalla SKR, Naseri HM, Kim BM, Katz SC, Armenio VA. Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States. J Natl Compr Canc Netw. 2018;16(4):370–6.PubMedCrossRef

13.

Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72(1):95–103.PubMedCrossRef

14.

Xia J, Jiang SC, Peng HJ. Association between liver fluke infection and hepatobiliary pathological changes: a systematic review and meta-analysis. PLoS ONE. 2015;10(7):e0132673.PubMedPubMedCentralCrossRef

15.

Li H, Hu B, Zhou ZQ, Guan J, Zhang ZY, Zhou GW. Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies. World J Surg Oncol. 2015;13:161.PubMedPubMedCentralCrossRef

16.

Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–62.PubMedPubMedCentralCrossRef

17.

Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.PubMedPubMedCentralCrossRef

18.

Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016;122(9):1349–69.PubMedCrossRef

19.

Zhang H, Zhu J, Ke F, Weng M, Wu X, Li M, et al. Radiological imaging for assessing the respectability of hilar cholangiocarcinoma: a systematic review and meta-analysis. Biomed Res Int. 2015;2015:497942.PubMedPubMedCentral

20.

Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, et al. Surgery for cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):143–55.PubMedPubMedCentralCrossRef

21.

Buckholz AP, Brown RS Jr. Cholangiocarcinoma: diagnosis and management. Clin Liver Dis. 2020;24(3):421–36.PubMedCrossRef

22.

Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(12):1015–27.PubMedCrossRef

23.••

Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022;40(18):2048–57. Phase III study that demonstrated clinical benefit of capecitabine adjuvantly.PubMedCrossRef

24.

Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.PubMedCrossRef

25.

Luvira V, Satitkarnmanee E, Pugkhem A, Kietpeerakool C, Lumbiganon P. Pattanittum P. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. Cochrane Database Syst Rev. 2021;9(9):Cd012814.PubMed

26.

Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.PubMedCrossRef

27.

Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–67.PubMedCrossRef

28.

Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401(10372):195–203.PubMedCrossRef

29.

Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617–22.PubMedCrossRef

30.

Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–40.PubMedCrossRef

31.

Breuer E, Mueller M, Doyle MB, Yang L, Darwish Murad S, Anwar IJ, et al. Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study. Ann Surg. 2022;276(5):846–53.PubMedCrossRef

32.

Azad AI, Rosen CB, Taner T, Heimbach JK, Gores GJ. Selected patients with unresectable perihilar cholangiocarcinoma (pCCA) derive long-term benefit from liver transplantation. Cancers (Basel). 2020;12(11):3157. https://doi.org/10.3390/cancers12113157.CrossRefPubMed

33.

Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88–98. e3; quiz e14.PubMedCrossRef

34.

Chang WW, Hsiao PK, Qin L, Chang CL, Chow JM, Wu SY. Treatment outcomes for unresectable intrahepatic cholangiocarcinoma: nationwide, population-based, cohort study based on propensity score matching with the Mahalanobis metric. Radiother Oncol. 2018;129(2):284–92.PubMedCrossRef

35.

Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, et al. Chemoradiation therapy for unresected extrahepatic cholangiocarcinoma: a propensity score-matched analysis. Ann Surg Oncol. 2017;24(13):4001–8.PubMedCrossRef

36.

Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.PubMedPubMedCentralCrossRef

37.

Kang H, Han SY, Cho JH, Kim EJ, Kim DU, Yang JK, et al. Efficacy and safety of temperature-controlled intraductal radiofrequency ablation in advanced malignant hilar biliary obstruction: a pilot multicenter randomized comparative trial. J Hepatobiliary Pancreat Sci. 2022;29(4):469–78.PubMedCrossRef

38.

Murakami T, Aizawa R, Matsuo Y, Hanazawa H, Taura K, Fukuda A, et al. Efficacy and safety of external-beam radiation therapy for unresectable primary or local recurrent cholangiocarcinoma. Cancer Diagn Progn. 2022;2(6):634–40.PubMedPubMedCentralCrossRef

39.••

Rachna T. Shroff KAG, Aaron James Scott, Mitesh J. Borad, Laura Williams Goff, Khalid Matin, et al. SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol. 2023;41(suppl 4; abstr LBA490). Phase III trial with negative results comparing triplets to doublet arm.

40.

Smith CEP, Prasad V. Targeted cancer therapies. Am Fam Physician. 2021;103(3):155–63.PubMed

41.

Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215–66.PubMedPubMedCentralCrossRef

42.

Vogel A, Segatto O, Stenzinger A, Saborowski A. FGFR2 Inhibition in cholangiocarcinoma. Annu Rev Med. 2023;74:293–306.PubMedCrossRef

43.

Kendre G, Murugesan K, Brummer T, Segatto O, Saborowski A, Vogel A. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol. 2023;78(3):614–26.PubMedCrossRef

44.

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84.PubMedPubMedCentralCrossRef

45.••

Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228–39. Phase II trial to show significant clinical benefit of an FGFR inhibitor.PubMedCrossRef

46.

Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, et al. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020;16(30):2385–99.PubMedPubMedCentralCrossRef

47.

Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, et al. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80(22):4986–97.PubMedCrossRef

48.

FDA D.I.S.C.O. Burst Edition: FDA approval of Lytgobi (futibatinib) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepaticcholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-discoburst-edition-fda-approval-lytgobi-futibatinib-adult-patients-previouslytreated#:~:text=On%20September%2030%2C%202022%2C%20the,gene%20fusions%20or%20other%20rearrangements. Accessed 1 May 2023.

49.

Hollebecque MB, Goyal L, Schram A, Park JO, Cassier PA, Kamath SD, et al. Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor(FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial. Annals of Oncology. 2022;33(suppl_7):S808–69. https://doi.org/10.1016/annonc/annonc1089.

50.

Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6(10):803–15.PubMedCrossRef

51.

October 10, 2022: Important information about Truseltiq. https://www.ccanewsonline.com/web-exclusives/press-releases/october-10-2022-trusel2q. Accessed 1 May 2023.

52.

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120(2):165–71.PubMedCrossRef

53.

Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751–65.PubMedPubMedCentralCrossRef

54.

Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012;18(20):5562–71.PubMedPubMedCentralCrossRef

55.

Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807.PubMedPubMedCentralCrossRef

56.

Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669–77.PubMedCrossRef

57.

Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34.PubMedCrossRef

58.

Leepisuth P, Watcharadetwittaya S, Sa-Ngiamwibool P. Tropomyosin receptor kinase protein expression in Thai cholangiocarcinoma: clinicopathological correlation, expression pattern, and prognosis. Ann Diagn Pathol. 2022;60:151996.PubMedCrossRef

59.

Demols A, Rocq L, Charry M, Nève ND, Verrellen A, Ramadhan A, et al. NTRK gene fusions in biliary tract cancers. Journal of Clinical Oncology. 2020;38(4_suppl):574.CrossRef

60.

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–82.PubMedCrossRef

61.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9.PubMedPubMedCentralCrossRef

62.

Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–85.PubMedCrossRef

63.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.PubMedPubMedCentralCrossRef

64.

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.PubMedCrossRef

65.

Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, Fazio N, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 2017;36(1):141–57.PubMedCrossRef

66.

Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290–300.PubMedCrossRef

67.

Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022;23(12):1558–70.PubMedCrossRef

68.

Harding JJ, Piha-Paul SA, Shah RH, Murphy JJ, Cleary JM, Shapiro GI, et al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun. 2023;14(1):630.PubMedPubMedCentralCrossRef

69.••

Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, et al. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 2022;18(19):2351–60. Emerging targets in cholangiocarcinoma.PubMedCrossRef

70.

Ritterhouse LL, Barletta JA. BRAF V600E mutation-specific antibody: a review. Semin Diagn Pathol. 2015;32(5):400–8.PubMedCrossRef

71.

Robertson S, Hyder O, Dodson R, Nayar SK, Poling J, Beierl K, et al. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol. 2013;44(12):2768–73.PubMedCrossRef

72.••

Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–43. Positive results from this trial contributed to the agnostic approval of the combination in solid tumors.PubMedCrossRef

73.

Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM, Bindra RS. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375):eaal2463. https://doi.org/10.1126/scitranslmed.aal2463.CrossRefPubMedPubMedCentral

74.

Kam AE, Masood A, Shroff RT. Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol Hepatol. 2021;6(11):956–69.PubMedCrossRef

75.••

Terrero G, Datta J, Pollack T, Naveda A, Abushahin LI, Sussman DA, et al. Exceptional sustained responses to ipilimumab/nivolumab (ipi/nivo) in patients (pts) with advanced pancreaticobiliary cancers and germline DNA damage repair (DDR) mutations. Journal of Clinical Oncology. 2020;38(15_suppl):e16757. Small data to show exceptional responders with DNA damage repair genes using immunotherapy.CrossRef

76.

Wu Z, Tao H, Zhang S, Wang X, Ma J, Li R, et al. Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting. Cancer Immunol Immunother. 2021;70(10):2971–80.PubMedPubMedCentralCrossRef

77.

Bukhari AB, Lewis CW, Pearce JJ, Luong D, Chan GK, Gamper AM. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis. J Clin Invest. 2019;129(3):1329–44.PubMedPubMedCentralCrossRef

78.

Gönül Geyik Ö, Anichini G, Ulukaya E, Marra F, Raggi C. DNA damage response inhibitors in cholangiocarcinoma: current progress and perspectives. Cells. 2022;11(9):1463. https://doi.org/10.3390/cells11091463.CrossRefPubMedPubMedCentral

79.

Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, et al. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020;16(30):2375–84.PubMedCrossRef

80.

Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017;7(3):252–63.PubMedCrossRef

81.

TEMPUS: Oncology FAQs 2023 [Available from: https://www.tempus.com/resources/faqs-oncology/#:~:text=What%20is%20Tempus'%20turnaround%20time,all%20required%20specimens%20are%20received. Accessed 1 May 1 2023.

82.

Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131.PubMedPubMedCentralCrossRef

83.

Rodon Font N, No Garbarino Y, Díaz Castello O, Moya Amoros J, Barrios Sánchez P, Coroleu Lletget D, et al. Concordance analysis between liquid biopsy (ctDNA) and tumor DNA molecular profiles from panel-based next-generation sequencing. Rev Esp Patol. 2022;55(3):156–62.PubMed

84.

Park S, Olsen S, Ku BM, Lee MS, Jung HA, Sun JM, et al. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Cancer. 2021;127(16):3019–28.PubMedCrossRef

85.

Bieg-Bourne CC, Okamura R, Kurzrock R. Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden. Mol Oncol. 2020;14(6):1242–51.PubMedPubMedCentralCrossRef

86.

Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC. Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov. 2021;11(4):874–99.PubMedCrossRef

87.

Wu Q, Zhen Y, Shi L, Vu P, Greninger P, Adil R, et al. EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2022;12(5):1378–95.PubMedPubMedCentralCrossRef

88.

Molyneaux M, Xu J, Evans DM, Lu P. Effect on tumor growth by TGF-β1/COX-2 siRNA combination product (STP705) in a human cholangiocarcinoma (HuCCT-1) xenograft tumor model in nude mice. J Clin Oncol. 2019;37(15):e14652.CrossRef

89.

Feng KC, Guo YL, Liu Y, Dai HR, Wang Y, Lv HY, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol. 2017;10(1):4.PubMedPubMedCentralCrossRef

90.

Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q, et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res. 2018;24(6):1277–86.PubMedCrossRef

91.

Keilson JM, Lindsey S, Bachini M, Medin CR, Berk A, Cornew S, et al. Patient reported outcomes: financial toxicity is a barrier to clinical trials and personalized therapy in cholangiocarcinoma. J Surg Oncol. 2022;126(6):1003–10.PubMedCrossRef

92.

Narang AK, Nicholas LH. Out-of-pocket spending and financial burden among medicare beneficiaries with cancer. JAMA Oncol. 2017;3(6):757–65.PubMedPubMedCentralCrossRef

93.

Rekulapelli A, Desai RP, Narayan A, Martin LW, Hall R, Larner JM, et al. Racial and treatment center differences on time to treatment initiation for nonsmall cell lung cancer patients receiving radiation therapy as an initial Treatment. Health Equity. 2022;6(1):603–9.PubMedPubMedCentralCrossRef

94.

Lee RJ, Madan RA, Kim J, Posadas EM, Yu EY. Disparities in cancer care and the Asian American population. Oncologist. 2021;26(6):453–60.PubMedPubMedCentralCrossRef

Title: An Overview of the Therapeutic Development of Cholangiocarcinoma with Special Emphasis on Targeted and Biologic Therapies
Authors: Paulina S. Marell
Jana Wieland
Hani M. Babiker
Lionel Kankeu Fonkoua
Mitesh J. Borad
Aminah Jatoi
Nguyen H. Tran
Publication date: 28-06-2023
Publisher: Springer US
Keywords: Cholangiocarcinoma
Cholangiocarcinoma
Targeted Therapy
Entrectinib
Cytostatic Therapy
Published in: Current Hepatology Reports / Issue 3/2023
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-023-00607-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2023

Nodular Regenerative Hyperplasia

Magnetic Resonance Imaging-Based Surveillance of Hepatocellular Carcinoma: Current Status and Future Perspectives

Extrahepatic Manifestations of Hepatitis B

Schistosomiasis: Hepatosplenic Disease and Portal Hypertensive Complications

Chemoprevention in hepatocellular carcinoma

Non-Cirrhotic Portal Hypertension in Children: Current Management Strategies

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials